ALK and non-small cell lung carcinoma: Then, alectinib, brigatinib, and lorlatinib were demonstrated to be superior to crizotinib on 12‐month EFS rate, ORR, and intracranial response in untreated ALK‐positive NSCLC.186, 187, 188